Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 1
2018 3
2019 4
2020 3
2021 5
2022 3
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Maintenance strategies after anti-EGFR-based induction in metastatic colorectal cancer: A systematic review and bayesian network meta-analysis.
Mastrantoni L, Beccia V, Caira G, Trovato G, Calegari MA, Basso M, Salvatore L, Pozzo C, Tortora G, Bria E, Orlandi A. Mastrantoni L, et al. Among authors: calegari ma. Crit Rev Oncol Hematol. 2023 Nov;191:104106. doi: 10.1016/j.critrevonc.2023.104106. Epub 2023 Sep 1. Crit Rev Oncol Hematol. 2023. PMID: 37659764 Free article. Review.
Irinotecan- vs. Oxaliplatin-Based Doublets in KRASG12C-Mutated Metastatic Colorectal Cancer-A Multicentre Propensity-Score-Matched Retrospective Analysis.
Formica V, Morelli C, Conca V, Calegari MA, Lucchetti J, Dell'Aquila E, Schirripa M, Messina M, Salvatore L, Lo Prinzi F, Dima G, Trovato G, Riondino S, Roselli M, Skoulidis F, Arkenau HT, Cremolini C. Formica V, et al. Among authors: calegari ma. Cancers (Basel). 2023 Jun 5;15(11):3064. doi: 10.3390/cancers15113064. Cancers (Basel). 2023. PMID: 37297026 Free PMC article.
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.
Morano F, Raimondi A, Pagani F, Lonardi S, Salvatore L, Cremolini C, Murgioni S, Randon G, Palermo F, Antonuzzo L, Pella N, Racca P, Prisciandaro M, Niger M, Corti F, Bergamo F, Zaniboni A, Ratti M, Palazzo M, Cagnazzo C, Calegari MA, Marmorino F, Capone I, Conca E, Busico A, Brich S, Tamborini E, Perrone F, Di Maio M, Milione M, Di Bartolomeo M, de Braud F, Pietrantonio F. Morano F, et al. Among authors: calegari ma. J Clin Oncol. 2022 May 10;40(14):1562-1573. doi: 10.1200/JCO.21.02583. Epub 2022 Mar 8. J Clin Oncol. 2022. PMID: 35258987 Free PMC article. Clinical Trial.
Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer.
Zurlo IV, Schino M, Strippoli A, Calegari MA, Cocomazzi A, Cassano A, Pozzo C, Di Salvatore M, Ricci R, Barone C, Bria E, Tortora G, Larocca LM, Basso M, Martini M. Zurlo IV, et al. Among authors: calegari ma. Cancer Immunol Immunother. 2022 Jan;71(1):45-55. doi: 10.1007/s00262-021-02960-1. Epub 2021 May 19. Cancer Immunol Immunother. 2022. PMID: 34009410 Free PMC article.
Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study.
Signorelli C, Calegari MA, Basso M, Anghelone A, Lucchetti J, Minelli A, Angotti L, Zurlo IV, Schirripa M, Chilelli MG, Morelli C, Dell'Aquila E, Cosimati A, Gemma D, Ribelli M, Emiliani A, Corsi DC, Arrivi G, Mazzuca F, Zoratto F, Morandi MG, Santamaria F, Saltarelli R, Ruggeri EM. Signorelli C, et al. Among authors: calegari ma. Curr Oncol. 2023 Jun 4;30(6):5456-5469. doi: 10.3390/curroncol30060413. Curr Oncol. 2023. PMID: 37366896 Free PMC article.
Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients.
Salvatore L, Bensi M, Vivolo R, Zurlo IV, Dell'Aquila E, Grande R, Anghelone A, Emiliani A, Citarella F, Calegari MA, Ribelli M, Basso M, Pozzo C, Tortora G. Salvatore L, et al. Among authors: calegari ma. Front Oncol. 2023 Feb 21;13:1125013. doi: 10.3389/fonc.2023.1125013. eCollection 2023. Front Oncol. 2023. PMID: 36895480 Free PMC article.
LUX-Lung 7: is there enough data for a final conclusion?
Orlandi A, Calegari MA, Barone C. Orlandi A, et al. Among authors: calegari ma. Lancet Oncol. 2016 Jul;17(7):e267-e268. doi: 10.1016/S1470-2045(16)30216-9. Lancet Oncol. 2016. PMID: 27396644 No abstract available.
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
Moretto R, Elliott A, Rossini D, Intini R, Conca V, Pietrantonio F, Sartore-Bianchi A, Antoniotti C, Rasola C, Scartozzi M, Salati M, Pella N, Calegari MA, Carullo M, Corti F, Mauri G, Fassan M, Masi G, Brodskiy P, Lenz HJ, Shields A, Lonardi S, Korn M, Cremolini C. Moretto R, et al. Among authors: calegari ma. Br J Cancer. 2022 Sep;127(5):957-967. doi: 10.1038/s41416-022-01852-0. Epub 2022 Jun 3. Br J Cancer. 2022. PMID: 35665778 Free PMC article.
25 results